Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (FR:NANO)
:NANO
Top Page
Nanobiotix
(LSE:NANO)
Select Model
Select Model
Rating:48Neutral
Price Target:
€5.50
▼(-75.34% Downside)
Nanobiotix's overall stock score is heavily impacted by its weak financial performance, characterized by negative profitability and high leverage. The technical analysis provides some positive momentum, but valuation concerns due to the negative P/E ratio and lack of dividend yield further weigh down the score.
Positive Factors
Negative Factors
Nanobiotix (NANO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.14B
Dividend YieldN/A
Average Volume (3M)643.25K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,943,150
10 Day Avg. Volume728,063
30 Day Avg. Volume643,246
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-2.17
Price to Sales (P/S)-12.30
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.00Price Target Upside-1.35% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Nanobiotix Business Overview & Revenue Model
Company DescriptionNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
How the Company Makes MoneyNanobiotix generates revenue primarily through collaborations and partnerships with pharmaceutical companies and healthcare institutions. The company may earn income from licensing agreements related to its innovative technologies and products, as well as from clinical trial collaborations that advance its product pipeline. Additionally, revenue may stem from the commercialization of its products, particularly if NBTXR3 and other therapies receive regulatory approval and enter the market. Key partnerships with larger pharmaceutical firms can also provide financial support and shared resources, contributing to the company's earnings potential.
Nanobiotix Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with strong collaborations, especially with JNJ, advancements in clinical trials, and financial strategies to ensure sustainability. Despite financial lowlights such as negative revenue impacts and increased net loss, the strategic developments and pipeline progress suggest a promising future.Q4-2024 Updates
Positive Updates
Strong Partnership with Johnson & Johnson
Nanobiotix has made significant progress with its collaboration with JNJ, which includes a $2.6 billion agreement with potential royalties. The collaboration is expanding into different indications such as lung cancer and head and neck cancer, potentially addressing over 100,000 patients and a $10 billion market in the US and EU5.
Progress in Clinical Trials
Multiple clinical trials are advancing well, including the pivotal Phase 3 study NANORAY-312 for head and neck cancer and the Phase 2 CONVERGE study for lung cancer initiated by JNJ. Early-stage trials show promising data in various cancers such as pancreatic, lung, and esophageal cancer.
Financial Strategy and Sustainability
Nanobiotix has extended its cash runway to mid-2026 and is exploring nondilutive financing to extend it further into 2027. The company has also amended its agreement with JNJ, reducing its funding obligations and improving its financial outlook.
Launch of Curadigm Platform
The company launched Curadigm, a next-generation nanotherapeutic platform, expected to impact multiple therapeutic areas and create potential partnerships with biotech and pharma industries.
Negative Updates
Negative Revenue Impact
Nanobiotix reported negative revenue of €7.2 million for 2024 due to the transfer of the NANORAY-312 study sponsorship to JNJ, which led to a negative €19.3 million revenue impact. This was a non-cash item but affected financial results.
Increased Net Loss
The net loss attributable to shareholders increased by 72% to €68.1 million for 2024, primarily due to the negative revenue recognition impact.
Company Guidance
In the recent conference call, Nanobiotix provided comprehensive guidance on its financial and operational achievements for the fiscal year 2024, along with future projections. The company highlighted its collaboration with Johnson & Johnson, which involves a $2.6 billion plus royalties agreement, focusing on NBTXR3, now branded as JNJ-1900, targeting lung and head and neck cancers. This collaboration alone could potentially address over 100,000 patients in the U.S. and EU5, translating into a $10 billion market opportunity. Nanobiotix also launched its Curadigm platform, a first-in-class product poised to address multiple therapeutic areas. Financially, the company received a $20 million milestone payment in 2024 related to the NANORAY-312 trial and has extended its cash runway to mid-2026, with plans to explore nondilutive financing options to potentially extend this to 2027. The fiscal year concluded with a net loss increase of 72% to €68.1 million, primarily due to a onetime negative revenue impact from the transfer of study sponsorship to JNJ, which is a noncash item. The company ended 2024 with €49.7 million in cash and cash equivalents, compared to €75.3 million in the previous year.Nanobiotix Financial Statement Overview
Summary
Nanobiotix faces significant financial challenges, with declining revenues, negative profitability, and high leverage. The financial position is weak, characterized by negative equity and cash flow difficulties. The company needs to address its revenue generation and reduce operational inefficiencies to improve its financial health.Income Statement
The income statement reflects significant challenges with negative revenue and declining profitability. Gross Profit Margin and Net Profit Margin are negative, indicating that costs exceed revenues, which is unsustainable. Revenue has drastically decreased from 2023 to 2024, showcasing a negative growth trend. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and high operating costs relative to revenue.25
Negative
Balance Sheet
The balance sheet reveals a negative Stockholders' Equity, indicating more liabilities than assets, which is concerning. The Debt-to-Equity Ratio cannot be calculated due to negative equity, suggesting high financial risk. The Equity Ratio is also negative, reflecting financial instability. The company’s leverage is high, with liabilities exceeding assets, posing significant financial risk.20
Very Negative
Cash Flow
Cash flow analysis shows a negative Free Cash Flow, which has worsened over the year, suggesting potential liquidity issues. The Operating Cash Flow to Net Income ratio is negative, indicating cash outflows are exceeding negative earnings. The company is not generating sufficient cash to cover its operating needs, which could challenge future operations.30
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | -11.61M | 30.06M | 4.78M | 10.00K | 50.00K |
| Gross Profit | -11.61M | 30.06M | 3.28M | 2.65M | 2.33M |
| EBITDA | -61.62M | -30.09M | -53.78M | -47.26M | -31.49M |
| Net Income | -68.13M | -39.70M | -57.04M | -47.00M | -33.59M |
Balance Sheet | |||||
| Total Assets | 67.42M | 93.90M | 59.77M | 101.67M | 133.93M |
| Cash, Cash Equivalents and Short-Term Investments | 49.74M | 75.28M | 41.39M | 83.92M | 119.15M |
| Total Debt | 50.90M | 50.56M | 53.17M | 46.02M | 48.98M |
| Total Liabilities | 133.12M | 95.74M | 86.81M | 74.98M | 63.56M |
| Stockholders Equity | -65.70M | -1.84M | -27.05M | 26.69M | 70.36M |
Cash Flow | |||||
| Free Cash Flow | -20.40M | -12.81M | -38.11M | -31.24M | -28.34M |
| Operating Cash Flow | -19.55M | -12.48M | -38.02M | -31.00M | -28.24M |
| Investing Cash Flow | -955.00K | -349.00K | 138.00K | -242.00K | -112.00K |
| Financing Cash Flow | -5.13M | 46.77M | -5.65M | -4.05M | 111.77M |
Nanobiotix Technical Analysis
Positive
22.30
Price Trends
11.68
Positive
8.13
Positive
5.70
Positive
Market Momentum
3.87
Negative
78.66
Negative
81.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NANO, the sentiment is Positive. The current price of 22.3 is above the 20-day moving average (MA) of 17.65, above the 50-day MA of 11.68, and above the 200-day MA of 5.70, indicating a bullish trend. The MACD of 3.87 indicates Negative momentum. The RSI at 78.66 is Negative, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NANO.
Nanobiotix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | €136.83M | 3.82 | -52.76% | ― | -96.92% | -175.84% | |
60 Neutral | $181.83M | 104.57 | -51.06% | ― | -45.41% | -273.69% | |
58 Neutral | €6.31B | ― | -148.98% | ― | ― | 18.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €455.90M | ― | -152.03% | ― | ― | -20.97% | |
48 Neutral | €1.14B | ― | ― | ― | ― | ― | |
48 Neutral | $179.54M | ― | -271.32% | ― | -75.86% | -30.54% |
* Healthcare Sector Average
FR:NANO
Nanobiotix
22.30
17.79
394.24%
FR:GNFT
Genfit
3.70
-1.69
-31.35%
FR:IPH
Innate Pharma SA
1.84
0.04
2.00%
FR:ABVX
Abivax SA
78.50
68.97
723.71%
FR:DBV
DBV Technologies
2.92
2.20
306.69%
FR:OSE
OSE Immunotherapeutics SA
6.03
-4.33
-41.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.